Treatment of major depressive disorder and treatment resistant depression with 5-MeO-DMT: Impact of 25 years of non-traditional public scientific communication and education on clinical development and commercialization
Juliet Meccia, David Casimir, Sisi Li, Shahin Shams, Thomas A. Isenbarger, Mark Seelig
Psychedelics April 25, 2026 Peer reviewed DOI: 10.1016/j.psyche.2026.100019 via OpenAlex
Summary
The use of 5-MeO-DMT in informal settings over the past 25 years has shown promise in alleviating depressive symptoms, yet this knowledge remains largely unrecognized. Traditional drug development models often overlook findings from these alternative routes due to legal barriers that hinder formal clinical trials. Grassroots support and Indigenous knowledge have emerged as key drivers of anecdotal evidence for its therapeutic benefits. The article highlights communication gaps that impede the integration of 5-MeO-DMT into mainstream psychiatry and calls for improved data-sharing models.
Study at a glance
| Key finding | The article identifies critical communication gaps that hinder the integration of 5-MeO-DMT into mainstream psychiatry. |
|---|
Abstract
Over the past 25 years, the use of 5-MeO-DMT in informal and underground settings has contributed a substantial, yet underrecognized, body of knowledge relating to the efficacy of 5-MeO-DMT in alleviating depressive symptoms. Traditional models of drug development, typically characterized by structured trials and regulatory milestones, rarely consider findings from these alternative routes. The legal and regulatory barriers surrounding psychedelic compounds have delayed formal clinical investigation, while public channels and Indigenous knowledge have driven grassroots support and anecdotal evidence of therapeutic benefit. This article identifies critical communication gaps hindering the integration of 5-MeO-DMT into mainstream psychiatry, advocating for transparent data-sharing models that incorporate existing informal knowledge.